Human Papillomavirus Infections - Pipeline Review, H1 2014: Industry Trends and Forecast

449 views

Published on

Human Papillomavirus Infections - Pipeline Review, H1 2014 @ http://www.researchmoz.us/human-papillomavirus-infections-pipeline-review-h1-2014-report.html

This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Published in: Healthcare, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
449
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Human Papillomavirus Infections - Pipeline Review, H1 2014: Industry Trends and Forecast

  1. 1. Human Papillomavirus Infections - Pipeline Review, H1 2014 Human Papillomavirus Infections - Pipeline Review, H1 2014 Summary Global Markets Directs, Human Papillomavirus Infections - Pipeline Review, H1 2014, provides an overview of the Human Papillomavirus Infectionss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Human Papillomavirus Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Human Papillomavirus Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Human Papillomavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 7 list Of Figures 8 introduction 9 global Markets Direct Report Coverage 9 human Papillomavirus Infections Overview 10 therapeutics Development 11 pipeline Products For Human Papillomavirus Infections - Overview 11 pipeline Products For Human Papillomavirus Infections - Comparative Analysis 12 human Papillomavirus Infections - Therapeutics Under Development By Companies 13 human Papillomavirus Infections - Therapeutics Under Investigation By Universities/institutes 16 human Papillomavirus Infections - Pipeline Products Glance 18 late Stage Products 18 Human Papillomavirus Infections - Pipeline Review, H1 2014
  2. 2. clinical Stage Products 19 early Stage Products 20 unknown Stage Products 21 human Papillomavirus Infections - Products Under Development By Companies 22 human Papillomavirus Infections - Products Under Investigation By Universities/institutes 25 human Papillomavirus Infections - Companies Involved In Therapeutics Development 26 merck & Co., Inc. 26 takeda Pharmaceutical Company Limited 27 medigene Ag 28 chong Kun Dang Pharmaceutical Corp. 29 crucell N.v. 30 starpharma Holdings Limited 31 bharat Biotech International Limited 32 flugen, Inc. 33 biomas Ltd. 34 apovax, Inc. 35 genticel 36 genetic Immunity, Inc 37 vaxart, Inc. 38 irx Therapeutics, Inc. 39 selecta Biosciences, Inc. 40 spider Biotech S.r.l. 41 eyegene, Inc. 42 indian Immunologicals Limited 43 beijing Minhai Biotechnology Co., Ltd 44 coridon Pty Ltd 45 chongqing Zhifei Biological Products Co., Ltd. 46 redbiotec Ag 47 agilvax, Inc. 48 human Papillomavirus Infections - Therapeutics Assessment 49 assessment By Monotherapy Products 49 assessment By Target 50 assessment By Mechanism Of Action 53 assessment By Route Of Administration 56 assessment By Molecule Type 58 drug Profiles 61 v-503 - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 v-503 - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 procervix - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 as-101 - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 astodrimer - Drug Profile 68 product Description 68 mechanism Of Action 68 r&d Progress 68 celecoxib - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 av2-dm - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 eg-hpv - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 Human Papillomavirus Infections - Pipeline Review, H1 2014
  3. 3. first Generation Bivalent Hpv Vaccine - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 ckd-12201 - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 apovax-104-hpv - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 irx-3 - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 human Papillomavirus Vaccine - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 rbt-201 - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 vaccine For Hpv - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 aavlp Program - Drug Profile 80 product Description 80 mechanism Of Action 80 r&d Progress 80 human Papillomavirus Vaccine - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 ax-03 - Drug Profile 82 product Description 82 mechanism Of Action 82 r&d Progress 82 sb-105 - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 human Papilloma Virus Vaccine - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 kanda Human Papillomavirus Vaccine - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 4-valent Human Papillomavirus Vaccine - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 human Papilloma Virus Vaccine - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 rkp-00156 - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 human Papillomavirus Vaccine - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 Human Papillomavirus Infections - Pipeline Review, H1 2014
  4. 4. rg-1-vlp - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 hupaderm Vaccine - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 subunit Vaccine For Human Papillomavirus Infections - Drug Profile 92 product Description 92 mechanism Of Action 92 r&d Progress 92 pl-202 - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 94 product Description 94 mechanism Of Action 94 r&d Progress 94 human Papilloma Virus Vaccine - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 small Molecules For Bacterial And Viral Infections - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 multivalent Vaccine Candidate For Human Papillomavirus Infections - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 human Papilomavirus Vaccine - Drug Profile 99 product Description 99 mechanism Of Action 99 r&d Progress 99 small Molecules For Hpv Infections - Drug Profile 100 product Description 100 mechanism Of Action 100 r&d Progress 100 drug For Hpv - Drug Profile 102 product Description 102 mechanism Of Action 102 r&d Progress 102 therapeutic Hpv Vaccine - Drug Profile 103 product Description 103 mechanism Of Action 103 r&d Progress 103 second Generation Pentavalent Hpv Vaccine - Drug Profile 104 product Description 104 mechanism Of Action 104 r&d Progress 104 second Generation Trivalent Hpv Vaccine - Drug Profile 105 product Description 105 mechanism Of Action 105 r&d Progress 105 human Papillomavirus Infections - Recent Pipeline Updates 106 human Papillomavirus Infections - Dormant Projects 113 human Papillomavirus Infections - Discontinued Products 114 human Papillomavirus Infections - Product Development Milestones 115 featured News & Press Releases 115 feb 20, 2014: Fda Accepts For Review Mercks Biologics License Application For V503, Investigational 9-valent Human Papillomavirus Vaccine 115 nov 04, 2013: Mercks Investigational 9-valent Hpv Vaccine, V503, Prevented 97 Percent Of Cervical, Vaginal And Vulvar Pre-cancers Caused By Five Additional Hpv Types, In Phase Iii Study 115 oct 24, 2013: Merck Provides Update On Investigational 9-valent Hpv Vaccine V503 To U.s. Advisory Committee On Immunization Practices 117 may 09, 2013: Gsk Announces New Commitment With Gavi Alliance To Supply Cervical Cancer Vaccine 117 may 09, 2013: Merck Receives Significant Portion Of Unicef Human Papillomavirus Vaccine Tender 118 apr 30, 2013: Immunogenicity Of Two Doses Of Merck's Hpv Vaccine May Be As Effective As Three, Study Finds 119 Human Papillomavirus Infections - Pipeline Review, H1 2014
  5. 5. dec 19, 2012: Sirnaomics Advances New Sirna Therapeutics Against Hpv Infection And Cervical Cancer 119 dec 06, 2012: New Studies Demonstrate Gardasil Has Long Duration Of Protection From Hpv Disease 120 oct 18, 2012: Genticel Announces Positive Data From Phase I Trial Of Procervix In Women Infected With High-risk Hpv Before Appearance Of Cervical Lesions 121 oct 01, 2012: Kaiser Permanente Study Affirms Safety Of Hpv4 Vaccine For Adolescents And Young Women In Routine Clinical Care 122 appendix 123 methodology 123 coverage 123 secondary Research 123 primary Research 123 expert Panel Validation 123 contact Us 124 disclaimer 124 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Human Papillomavirus Infections - Pipeline Review, H1 2014

×